UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia

Cancer medicine (Malden, MA), 2024-09, Vol.13 (17), p.e70192-n/a

2024

Volltextzugriff (PDF)

Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience

Current oncology (Toronto), 2021-08, Vol.28 (4), p.3104-3114

2021

Volltextzugriff (PDF)

Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant

Current oncology (Toronto), 2020-12, Vol.28 (1), p.203-208

2020

Volltextzugriff (PDF)

Monoclonal gammopathy of undetermined significance and biological treatments: What should we do?

Joint, bone, spine : revue du rhumatisme, 2017-12, Vol.84 (6), p.651-653

Lemieux-Blanchard, Émilie

2017

Volltextzugriff (PDF)

Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study

Bone marrow transplantation (Basingstoke), 2022-02, Vol.57 (2), p.252-260

2022

Volltextzugriff (PDF)

Focused review on nutritional status of patients with immunoglobulin light chain amyloidosis

Current problems in cancer, 2022-06, Vol.46 (3), p.100833-100833, Article 100833

2022

Volltextzugriff (PDF)

Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia

Blood, 2004-01, Vol.103 (1), p.252-257

2004

Volltextzugriff (PDF)

Anatomy of a founder effect : myotonic dystrophy in northeastern quebec

Human genetics, 2005-07, Vol.117 (2-3), p.177-187

2005

Volltextzugriff (PDF)

Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments

Blood, 2023-11, Vol.142 (Supplement 1), p.3399-3399

2023

Volltextzugriff (PDF)

A Comprehensive Multidisciplinary Diagnostic Algorithm for the Early and Efficient Detection of Amyloidosis

Clinical lymphoma, myeloma and leukemia, 2023-03, Vol.23 (3), p.194-202

2023

Volltextzugriff (PDF)

Targeting Patient at High Risk of Thrombocytopenia and Neutropenia with Cybord, Vel-Dex and VMP: Time to Decrease the Number of Blood Tests ?

Blood, 2014-12, Vol.124 (21), p.1295-1295

2014

Volltextzugriff (PDF)

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Blood, 2017-12, Vol.130, p.1870-1870

2017

Volltextzugriff (PDF)

First Year Experience Of Subcutaneous Bortezomib Use In a University Teaching Hospital

Blood, 2013-11, Vol.122 (21), p.5610-5610

2013

Volltextzugriff (PDF)

HOUT-14. PROGNOSTIC IMPACT OF FIRST PSEUDOPROGRESSION ON MRI IN GLIOBLASTOMA, AN 11 YEARS EXPERIENCE FROM A CANADIAN UNIVERSITY CENTER

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi114-vi115

2019

Volltextzugriff (PDF)

HOUT-28. FIRST-LINE TEMOZOLOMIDE VS PCV FOR LOW GRADE GLIOMAS: A 11 YEARS REAL-WORLD DATA FROM CHUM, UNIVERSITY CENTER

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi118-vi118

2019

Volltextzugriff (PDF)

HOUT-23. ADULT MEDULLOBLASTOMA TREATMENT IMPACT SINCE 2006: A CANADIAN UNIVERSITY CENTER EXPERIENCE

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi117-vi117

2019

Volltextzugriff (PDF)

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Blood, 2017-12, Vol.130, p.4556-4556

2017

Volltextzugriff (PDF)

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other

Leukemia & lymphoma, 2014-09, Vol.55 (9), p.2165-2173

2014

Volltextzugriff (PDF)

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Blood, 2016-12, Vol.128 (22), p.2306-2306

2016

Volltextzugriff (PDF)

Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL

Pharmacogenomics, 2005-04, Vol.6 (3), p.293-302

2005

Volltextzugriff (PDF)

Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada

Blood, 2015-12, Vol.126 (23), p.5573-5573

2015

Volltextzugriff (PDF)

MGUS et traitements biologiques : que faire ?

Revue du rhumatisme (Ed. française : 1993), 2017-12, Vol.84 (6), p.472-474

Lemieux-Blanchard, Émilie

2017

Volltextzugriff (PDF)

BIOS-02. CLINICAL OUTCOMES OF OVER 600 PATIENTS WITH GLIOBLASTOMA TREATED AT A CANADIAN TERTIARY CENTER IN THE PAST 15 YEARS: A COMPARATIVE ANALYSIS WITH THE PIVOTAL STUPP TRIAL

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii20-vii21

2022

Volltextzugriff (PDF)

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Blood, 2018-11, Vol.132 (Supplement 1), p.4666-4666

2018

Volltextzugriff (PDF)

Multiple Myeloma Presenting as Acute Kidney Failure Secondary to Lambda Light Chain Deposition

Journal of Hematology Research, 2022-11, Vol.9, p.10-14

2022

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(30)

Sprache

Englisch
(29)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Humans
(8)
Oncology
(7)
Female
(4)
Male
(4)
Health Outcome Measures
(3)
Hematology
(3)
Multiple Myeloma
(3)
Prognosis
(3)
Treatment Outcome
(3)
Aged
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Biological And Medical Sciences
(2)
Chemotherapy
(2)
Child, Preschool
(2)
Cytogenetics
(2)
Flow Cytometry
(2)
Genetic Aspects
(2)
Internal Medicine
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia

Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience

Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant

Monoclonal gammopathy of undetermined significance and biological treatments: What should we do?

Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study

Focused review on nutritional status of patients with immunoglobulin light chain amyloidosis

Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia

Anatomy of a founder effect : myotonic dystrophy in northeastern quebec

Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments

A Comprehensive Multidisciplinary Diagnostic Algorithm for the Early and Efficient Detection of Amyloidosis

Targeting Patient at High Risk of Thrombocytopenia and Neutropenia with Cybord, Vel-Dex and VMP: Time to Decrease the Number of Blood Tests ?

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

First Year Experience Of Subcutaneous Bortezomib Use In a University Teaching Hospital

HOUT-14. PROGNOSTIC IMPACT OF FIRST PSEUDOPROGRESSION ON MRI IN GLIOBLASTOMA, AN 11 YEARS EXPERIENCE FROM A CANADIAN UNIVERSITY CENTER

HOUT-28. FIRST-LINE TEMOZOLOMIDE VS PCV FOR LOW GRADE GLIOMAS: A 11 YEARS REAL-WORLD DATA FROM CHUM, UNIVERSITY CENTER

HOUT-23. ADULT MEDULLOBLASTOMA TREATMENT IMPACT SINCE 2006: A CANADIAN UNIVERSITY CENTER EXPERIENCE

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL

Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada

MGUS et traitements biologiques : que faire ?

BIOS-02. CLINICAL OUTCOMES OF OVER 600 PATIENTS WITH GLIOBLASTOMA TREATED AT A CANADIAN TERTIARY CENTER IN THE PAST 15 YEARS: A COMPARATIVE ANALYSIS WITH THE PIVOTAL STUPP TRIAL

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Multiple Myeloma Presenting as Acute Kidney Failure Secondary to Lambda Light Chain Deposition

Suchergebnisse filtern